# argenx SE (ARGX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $901.12, market value $56.7 billion.

## Valuation
- **P/E (trailing): 31.2×** (5-yr avg 45.5×, 3-yr avg 45.5×). argenx SE trades at 31.2× trailing earnings, well below its own five-year average of 45.5×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 27.1×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.51**. A PEG of 0.51 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 9.7×**. Each dollar of revenue is priced at 9.7×.
- **Price / book: 7.7×**. The shares trade at 7.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 1.2%** (5-yr avg -1.7%). Free cash flow equals 1.2% of the market value, above its five-year average of -1.7%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 3.2%**. The inverse of the P/E: 3.2% of the price is earned each year.

## Profitability
- **Gross margin: 90.0%**. argenx SE keeps 90.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 29.8%**. 29.8% of revenue is left after running the business, an exceptional level.
- **Return on equity: 17.6%**. 17.6% on shareholders' equity is solid.
- **Return on assets: 21.6%**. Each dollar of assets produces 21.6% of profit.

## Growth
- **EPS growth (1 yr): 53.1%**. Earnings per share rose 53.1%.

## Financial health
- **Interest coverage: 452.6×**. Operating profit covers interest 452.6× over, a safe margin.
- **Current ratio: 5.23** (quick 5.23). Current assets cover the next year's liabilities 5.23 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. argenx SE does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (23 analysts). 23 analysts cover argenx SE; the consensus is buy, with an average price target of $1147.35 (+27% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 6.9%** (YTD 4.0%, 3-mo 5.3%). The shares are up 6.9% over twelve months including dividends.
- **From 52-week high: -16.0%** (36.2% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 46**. An RSI of 46 is neutral.
- **Beta (1 yr): 0.38** (volatility 37%). Beta of 0.38 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ARGX · Page: https://foliofundamentals.com/stocks/argx

Not investment advice.